Bone Abstracts

Mammalian target of rapamycin (mTOR) functions mainly in the form of two complexes, namely mTORC1 and mTORC2, which are distinct in their unique components, raptor and rictor. Here, we focused on bone phenotypes in mice with a specific deletion of rictor using a Cre recombinase gene whose expression was driven by the promoter of osteocalcin. All procedures involving mice were approved by the Institutional Animal Care and Use Committee of the local admin. DXA analysis showed a ...

Mammalian target of rapamycin (mTOR) functions mainly in the form of two complexes, namely mTORC1 and mTORC2, which are distinct in their unique components, raptor and rictor. Here, we focused on bone phenotypes in mice with a specific deletion of rictor using a Cre recombinase gene whose expression was driven by the promoter of osteocalcin. All procedures involving mice were approved by the Institutional Animal Care and Use Committee of the local admin. DXA analysis showed a ...

see PP447....

Treatment with sclerostin antibody (Scl-Ab) increases bone formation and strength in animal models. Here, we aimed to i) characterize the longer-term effects of Scl-Ab on bone in cynomolgus monkeys (cynos) and ovariectomized (OVX) rats and ii) test whether follow-up treatment with OPG-Fc would maintain the bone mass gains induced by Scl-Ab in OVX rats. In the cynos study, 3 to 5-year-old male cynos were treated for 6 months with weekly SC injections of vehicle (Veh), 3, 10, or...

Objective: Zoledronic acid (Zol) has been demonstrated to be an effective therapy to treat postmenopausal osteoporosis (PMO) in Chinese women in a 12-month post-marketing observational study (ZOOM study). As an I.V. bisphosphonates, Zol are exclusively excreted via the kidneys. We present a report of the renal function and safety data of once-yearly Zol 5 mg treatment.Subjects and methods: A total of 373 PMO patients from 30 different centers in China wi...

Screening gene function in vivo is a powerful approach to discover novel drug targets in the human genome (Nat Rev Drug Discov 2 38–51, 2003). We present data for 3776 distinct gene knockout (KO) mouse lines with viable adult homozygous mice generated using both gene-trapping and homologous recombination technologies. Bone mass was determined from PIXImus DEXA scans of male and female mice at 14 weeks of age and by microCT analyses of bones from ...

Objectives: Bone remodeling and maintenance require a fine balance between bone formation of osteoblasts and resorption of osteoclasts. Therefore, various skeletal disorders cause by imbalanced differentiation and activities of these cells. Receptor activator of NF-κB ligand (RANKL) induces Ca2+ oscillations and activates nuclear factor of activated T cells 1 (NFATc1) during osteoclast differentiation. Although Ca2+ oscillations play a key role for o...

Inhibition of an increase of osteoclasts has become the most important treatment for osteoporosis. The CXCR4 antagonist, AMD3100, plays an important role in the mobilization of osteoclast precursors within bone marrow (BM). However, the actual therapeutic impact of AMD3100 in osteoporosis has not yet been ascertained. Here we demonstrate the therapeutic effect of AMD3100 in the treatment of ovariectomy-induced osteoporosis in mice. We found that treatment with AMD3100 resulted...

Introduction: Most reports focused on clinical advantages of intervertebral cages; only a few studies reviewed the complications. As one of the major complications, cage migrating into vertebral body or spinal canal may result in disastrous consequence. Multiple risk factors may result in cage migration, such as geometric design of cage, surgical technique, the bone quality and post-operative protection. The following is a presentation of nine patients with migrated cage.<...

Introduction: Standard clinical treatments for postmenopausal osteoporosis utilize resorption-inhibiting drugs such as bisphosphonates, which selectively bind to bone mineral but also suppress bone formation over time. Prostaglandin E2 (PGE2) has bone-anabolic effects in vivo, but its clinical utility is hindered by side effects upon systemic administration. Since PGE2 acts on bone via the EP4 receptor, our approach utilizes a specific...